Physiologic insulin resensitization for adults with stage 3b–5 chronic kidney disease and type 2 diabetes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study compares physiologic insulin resensitization (PIR) to standard of care in adults with CKD stages 3b–5 and type 2 diabetes. Eligible participants are 18 or older, have T2DM for at least six months, and are on a stable regimen for complications; permitted diabetes therapies include oral agents, insulin, or GLP‑1 receptor agonists. PIR delivers patterned insulin intended to restore physiologic insulin signaling alongside routine nephrology management according to the study protocol. The study will track kidney-related outcomes and measures of diabetes control and compare results between the PIR and standard-care groups.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Is age 18 or older (male or female)
* Have a documented diagnosis of CKD stage 3b, 4, or 5 and T2DM of 6 months or greater prior to screening. Patients may have treatment regimens associated with T2DM that include diabetic oral and/or injectable medications including insulin and/or GLP-1 receptor agonists.
* In the opinion of the Investigator, has been on an appropriate, stable regimen for management of any complications present for the past six (6) months.
* In the opinion of the Investigator, is able to do all of the following:

  * Provide valid informed consent.
  * Understand and comply with study procedures as presented in the consent process.
  * Has the capacity or support to attend all required visits.
* If female, the subject must meet either of the following sets of conditions:

  o Is of non-childbearing potential, defined as meeting either of the following criteria:
* Age ≥50 years and post-menopausal for at least one (1) year
* Surgically sterile due to bilateral tubal ligation, bilateral oophorectomy, or hysterectomy
* Is of childbearing potential and meets both of the following criteria:

  * Has a negative serum pregnancy test (beta-human chorionic gonadotropin) at screening.
  * Agrees to practice an acceptable method of birth control (contraception) from screening until at least 30 days after last study treatment

Exclusion Criteria:

* Has in the past two (2) years received treatment for a malignancy.
* Current pregnancy or intends to become pregnant during the study
* Has in the past one (1) year used non-prescription opioids or psychoactive drugs.
* Has in the past six (6) months had a hypoglycemic event requiring urgent care and/or administration of glucagon, osteocalcin, or parenteral glucose, unless approved for enrollment by the Medical Monitor.
* Has within the past one (1) month participated in a clinical study involving either of the following:

  * An investigational drug or procedure for any clinical indication
  * An investigation method for glucose control using approved agents
* Is nursing or is planning to nurse during the study.
* Has at screening a positive test for HIV (4th gen. screen), HBsAg, or HCV viral load.
* Has at screening, one or more of the following abnormal lab results:

  * Hb \<8 g/dL
  * WBC \<2,000/µL
  * Platelets \<50,000/µL
  * ALT, AST, or Alkaline Phosphatase \>5x ULN
  * ALT or AST \>2.5x ULN, and Total Bilirubin \>2x ULN
  * Serum albumin \<3 g/dL
* Has - in the opinion of the Investigator - psychiatric, behavioral, cognitive and/or clinical dysfunction (whether or not related to known medical illness or drug / alcohol use) that would affect the subject's safety and/or compliance.
* Is on active dialysis at time of screening

Where it's running

• Arizona Kidney Disease and Hypertension Center
  Phoenix, Arizona, United States Recruiting
• Innovative Diabetic Center
  Scottsdale, Arizona, United States Recruiting

Study contacts

• Principal investigator: Sungchun Lee, MD — Arizona Kidney Disease and Hypertension Centers
• Study coordinator: Richard Marchase, PhD
• Email: rmarchase@gmail.com
• Phone: 205-612-4763

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Acute Blood Flow Restriction Walking in Type 2 Diabetes

  This study tests whether adding blood flow restriction to treadmill walking affects immune cells in adults with type 2 diabetes.

  Recruiting University of British Columbia · Kelowna, British Columbia · NCT07928531

• Continuous Glucose Monitoring in Type 2 Diabetes Not on Insulin

  This study tests whether using a continuous glucose monitoring system helps people with type 2 diabetes who aren’t using insulin to improve blood sugar control and quality of life.

  Recruiting Medical University of Bialystok · Bialystok · NCT07919236

• Differentiating heart disease in autoimmune vs. type 2 diabetes

  This study tests whether adult-onset autoimmune diabetes (AID/LADA) and type 2 diabetes (T2D) differ in how diabetic heart disease develops, using advanced heart imaging in people with AID, T2D, and healthy controls.

  Recruiting University of Roma La Sapienza · Rome, Roma · NCT07911007

• Lifestyle Metabotype Study B: Understanding Personalized Glucose Responses

  This study tests how lifestyle, metabolism, and brain energy use relate to each person’s blood sugar response after meals, across people with and without prediabetes or type 2 diabetes.

  Recruiting at 2 sites German Institute of Human Nutrition · Berlin and 1 other locations · NCT07888257

• Lifestyle Metabotype Study: How Daily Habits Shape Blood Sugar

  This observational study tests whether personal lifestyle and biological factors can predict how a person’s blood sugar responds after meals.

  Recruiting German Institute of Human Nutrition · Potsdam, Potsdam-Rehbrücke · NCT07868601

• Switching to Zenagamtide From Tirzepatide in Adults With Overweight or Obesity With or Without Type 2 Diabetes

  This study tests whether adults who are overweight or have obesity (with or without type 2 diabetes) can switch from tirzepatide to a new treatment called zenagamtide to find a tolerable dose.

  Recruiting at 2 sites Phase 1 Novo Nordisk A/S · Glendale, California and 1 other locations · NCT07868354

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.